'Dasatinib' diaporamas de présentation

Michael J. Mauro MD

764 views • 60 slides

CML & MPDs Practitioner Conference CML: Cases and interactive voting

CML & MPDs Practitioner Conference CML: Cases and interactive voting. Brian Huntly University of Cambridge and Addenbrookes Hospital. Case 1. 37 year old male WCC 80, Plts 840, Baso 6%, Blasts 2%, no spleen BCR-ABL positive, Sokal/Hasford low-risk 3 siblings

427 views • 31 slides

CML & MPDs Practitioner Conference CML: Cases and interactive voting

CML & MPDs Practitioner Conference CML: Cases and interactive voting. Brian Huntly University of Cambridge and Addenbrookes Hospital. Case 1. 37 year old male WCC 80, Plts 840, Baso 6%, Blasts 2%, no spleen BCR-ABL positive, Sokal/Hasford low-risk 3 siblings

314 views • 31 slides

Shah N et al. Proc ASH 2010;Abstract 206.

Dasatinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the DASISION Trial: 18-Month Follow-Up. Shah N et al. Proc ASH 2010;Abstract 206. DASISION Study Schema. Dasatinib 100mg PO QD (n = 259). R. Imatinib 400mg PO QD

370 views • 12 slides

Kantarjian H et al. Proc ASCO 2011;Abstract 6510.

Dasatinib or Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Two-Year Follow-Up from DASISION. Kantarjian H et al. Proc ASCO 2011;Abstract 6510. DASISION Study Design. Dasatinib 100 mg QD (n = 259). R. Follow-up. 5 yrs. Imatinib 400 mg QD (n = 260).

251 views • 8 slides

42.8%

Dasatinib + etoposide. 0.1?M dasatinib. 0.1?M Eto. Control. With DEAB. Without DEAB. The proportion of ALDH1-positive. 24.4%. 42.8%. 38.5%. 43.1%.

123 views • 1 slides

3.49%

Dasatinib + etoposide. 0.1?M dasatinib. 0.1?M Eto. Control. With DEAB. Without DEAB. The proportion of ALDH1-positive. 5.25%. 3.49%. 7.81%. 3.29%.

120 views • 1 slides